Adam Koppel - 02 Dec 2022 Form 3 Insider Report for Solid Biosciences Inc. (SLDB)

Role: Director, 10%+ Owner
Signature: /s/ Adam Koppel
Issuer symbol: SLDB
Transactions as of: 02 Dec 2022
Net transactions value: $0
Form type: 3
Filing time: 05 Dec 2022, 15:58:00 UTC
Previous filing: 22 Jun 2022
Next filing: 15 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	SLDB	Common Stock						3,130,423	02 Dec 2022	See footnotes	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of the Issuer's Common Stock held by BCLS SB Investco, LP ("BCLS SB"), Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), BCLS II Investco, LP ("BCLS II Investco") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS SB, BCLS Fund II and BCLS II Investco, the "Bain Capital Life Sciences Entities").
F2	Dr. Koppel is a Managing Director of Bain Capital Life Sciences Investors, LLC ("BCLSI"). BCLSI (i) is the ultimate general partner of each of BCLS SB, BCLS Fund II and BCLS II Investco and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.

Content

Represents shares of the Issuer's Common Stock held by BCLS SB Investco, LP ("BCLS SB"), Bain Capital Life Sciences Fund II, L.P. ("BCLS Fund II"), BCLS II Investco, LP ("BCLS II Investco") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS SB, BCLS Fund II and BCLS II Investco, the "Bain Capital Life Sciences Entities").

Dr. Koppel is a Managing Director of Bain Capital Life Sciences Investors, LLC ("BCLSI"). BCLSI (i) is the ultimate general partner of each of BCLS SB, BCLS Fund II and BCLS II Investco and (ii) governs the investment strategy and decision-making process with respect to investments held by BCIPLS. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Dr. Koppel disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.